Edgar Filing: TITAN PHARMACEUTICALS INC - Form 4

TITAN PHA Form 4 February 21	ARMACEUTICA	LS INC									
									PPROVAL		
-	UNITED	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549					N OMB Number:	3235-0287			
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). STATEMENT OF CHANGES IN BENEFICIAL OV SECURITIES Filed pursuant to Section 16(a) of the Securities Exchar Section 17(a) of the Public Utility Holding Company Act 30(h) of the Investment Company Act of 1							Estimated average burden hours per response ange Act of 1934, t of 1935 or Section				
(Print or Type	Responses)										
1. Name and A MACFARI	2. Issuer Name and Ticker or Trading Symbol TITAN PHARMACEUTICALS IN [TTNP]				5. Relationship of Reporting Person(s) to Issuer VC (Check all applicable)						
(Last) C/O TITAN INC, 400 C	3. Date of Earliest Transaction (Month/Day/Year) 02/16/2017				X_Director10% Owner Officer (give titleOther (specify below)below)						
	4. If Amendment, Date Original Filed(Month/Day/Year)				 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting 						
S SAN FRA	ANCISCO, CA 94	4080					Person	More than One R	eporting		
(City)	(State)	(Zip)	Tab	ole I - Non-l	Derivative	Securities A	cquired, Disposed	of, or Beneficia	lly Owned		
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)		Date, if	3. Transactio Code (Instr. 8) Code V	Disposed (Instr. 3, 4	(A) or of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
Reminder: Re	port on a separate line	e for each cla	ass of sec	urities bene	ficially ow	ned directly	or indirectly.				
Persor inform require							ons who respond to the collection of mation contained in this form are not ired to respond unless the form lays a currently valid OMB controlSEC 1474 (9-02)				
	Tab				-	posed of, or convertible	Beneficially Owner securities)	d			

1. Title of	2.	3. Transaction Date	3A. Deemed	4. 5.	Number of	6. Date Exercisable and	7. Title and Amount of
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	TransactionDe	erivative	Expiration Date	Underlying Securities

Edgar Filing: TITAN PHARMACEUTICALS INC - Form 4

Security (Instr. 3)	•		y ionth/Day/Year)	Code (Instr. 8)	Securitie Acquired or Dispo (D) (Instr. 3, and 5)	l (A) sed of	(Month/Day/Year)		(Instr. 3 and 4)	
				Code N	′ (A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option to Purchase Common Stock	\$ 3.8	02/16/2017		A	10,000)	02/16/2017	02/16/2027	Common Stock	10,000
Reporting Owners										
Reporting Owner Name / Address			Relationships							
			Director 10	% Owner	Officer	Other	r			
MACFARLANE M DAVID C/O TITAN PHARMACEUTICALS INC 400 OYSTER POINT BLVD S SAN FRANCISCO, CA 94080		Х								
Signat	tures									
/S/ M. Da MacFarlan	vid	02/21/2017								
<u>**</u> Signature c Pers		Date								

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.